Michael Rocco to Disease Progression
This is a "connection" page, showing publications Michael Rocco has written about Disease Progression.
Connection Strength
0.325
-
Kramer H, Berns JS, Choi MJ, Martin K, Rocco MV. 25-Hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. Am J Kidney Dis. 2014 Oct; 64(4):499-509.
Score: 0.106
-
Rocco MV. More frequent hemodialysis: back to the future? Adv Chronic Kidney Dis. 2007 Jul; 14(3):e1-9.
Score: 0.065
-
Macedo E, Hemmila U, Sharma SK, Claure-Del Granado R, Mzinganjira H, Burdmann EA, Cerdá J, Feehally J, Finkelstein F, García-García G, Jha V, Lameire NH, Lee E, Levin NW, Lewington A, Lombardi R, Rocco MV, Aronoff-Spencer E, Tonelli M, Yeates K, Remuzzi G, Mehta RL. Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility study. PLoS Med. 2021 01; 18(1):e1003408.
Score: 0.042
-
Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, Rastogi A, Cheung AK, Freedman BI, Punzi H, Rocco MV, Ix JH, Shlipak MG. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin J Am Soc Nephrol. 2020 03 06; 15(3):349-358.
Score: 0.039
-
Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T. Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol. 2019 08; 30(8):1523-1533.
Score: 0.037
-
Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Am J Kidney Dis. 2018 12; 72(6):873-884.
Score: 0.035